Skip to main content
37 search results for:

Scleroderma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 05-05-2020 | Systemic sclerosis | News | Article
    News in brief

    ​​​​​​​World Scleroderma Foundation issues preliminary advice on SSc and COVID-19

    The World Scleroderma Foundation has released preliminary guidance to address questions on COVID-19 in patients with systemic sclerosis.

  2. 10-01-2018 | Respiratory disorders | Article

    Interstitial lung disease in systemic sclerosis: Data from the Spanish scleroderma study group

    Sánchez-Cano D et al. Rheumatol Int 2018; 38: 363–374. doi: 10.1007/s00296-017-3916-x

  3. 26-07-2018 | Scleroderma | Article

    Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial

    Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213

  4. 01-09-2016 | Scleroderma | Article

    An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial

    Khanna D et al. J Rheumatol 216; 43: 1672–1679. doi: 10.3899/jrheum.151322

  5. 02-12-2022 | Systemic sclerosis | News | Article
    News in brief

    Anti-SSSCA1 positivity tied to cancer risk in SSc patients

    medwireNews : Study findings reported in Rheumatology suggest that anti-Sjögren’s syndrome/scleroderma autoantigen 1 (SSSCA1) antibodies may warrant further investigation as a biomarker for cancer risk among patients with systemic sclerosis (SSc).

  6. 25-03-2022 | Systemic sclerosis | Adis Journal Club | Article
    Rheumatology and Therapy

    Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers

    In this study, a preliminary evaluation of the role and effectiveness of blue light photobiomodulation (PBM) therapy with EmoLED® in the treatment of scleroderma skin ulcers (SSc-SU) was performed.

  7. 03-12-2021 | Systemic sclerosis | News | Article

    Targeting pain should be a priority in systemic sclerosis

    For the study, Yvonne Lee (Northwestern University Feinberg School of Medicine, Chicago, USA) and co-researchers evaluated the experience of pain in 2157 people with SSc from the Scleroderma Patient-centered Intervention Network cohort.

  8. 21-04-2021 | COVID-19 | News | Article

    Benefits of video chat-based mental health support unclear in systemic sclerosis

    She adds that “the SPIN-CHAT Program led to small positive improvements in anxiety, which has the potential to improve the quality of life of patients with scleroderma during a particularly anxiety-provoking time.

  9. 11-11-2020 | ACR 2020 | Conference coverage | Article

    Survey sheds light on rheumatology provider experiences during COVID-19 pandemic

    However, between 41% and 53% preferred an in-person visit for people with lupus, scleroderma, vasculitis with immunosuppressive or glucocorticoid dose changes, and RA or spondyloarthritis with active medication (DMARD/biologic) changes.

  10. 09-10-2020 | Systemic sclerosis | News | Article

    Early data show benefits of romilkimab in diffuse cutaneous SSc

    Two patients in the romilkimab group and one in the placebo group permanently discontinued treatment as a result of esophageal stenosis, scleroderma renal crisis, and cardiomyopathy, respectively.

  11. 21-11-2019 | Rheumatoid arthritis | News | Article

    RA comorbidities signal a need to screen

    These were pulmonary fibrosis (odds ratio [OR]=4.63), systemic lupus erythematosus or scleroderma (OR=4.44), fibromyalgia (OR=2.67), inflammatory bowel disease (OR=2.63), myocardial infarction (OR=2.15), epilepsy (OR=2.13), venous thromboembolism (VTE; OR=1.85), osteoarthritis (OR=1.70), OSA (OR=1.44), gastroesophageal reflux disease (OR=1.47), and cataracts (OR=1.38).

  12. 15-05-2020 | Systemic sclerosis | News | Article

    Faster progression of SSc expected for patients over 60 years at disease onset

    The researchers used data from 3281 SSc patients (79.7% female) who were enrolled in the registry of the German Network for Systemic Scleroderma, of whom 54.2% had limited cutaneous (lc)SSc, 34.8% had diffuse cutaneous (dc)SSc, and the remaining 11.0% had overlap SSc.

  13. 07-05-2020 | Systemic sclerosis | News | Article

    Concise self-management hand program effective for SSc patients

    “Due to the rarity of SSc, scleroderma hand care – especially occupational therapy – is not often available and is generally restricted to specialized centers, usually far from patients’ residences, which limits enrolment and adherence,” say Eduardo Magalhães (University of Campinas-Unicamp, São Paulo, Brazil) and colleagues.

  14. 12-12-2019 | Risk prediction | News | Article

    Family history of certain conditions may predict RA risk

    Other significant risk factors included pulmonary fibrosis (OR=2.12), rheumatologic autoimmune diseases such as scleroderma and systemic lupus erythematosus (OR=1.89), inflammatory bowel disease (OR=1.45), OA, (OR=1.41), hyper/hypothyroidism, fibromyalgia (OR=1.34), obstructive sleep apnea (OR=1.28), and migraine headaches (OR=1.20).

  15. 09-10-2019 | Systemic sclerosis | News | Article

    Immunosuppressive therapy reduces progression of mild ILD in patients with SSc

    The patients were identified from the Canadian Scleroderma Research Group Registry.

  16. 18-06-2019 | Systemic sclerosis | EULAR 2019 | Article
    News in brief

    Nintedanib reduces SSc-ILD progression across various subgroups

    In light of these results, Distler noted that the regulatory submission for nintedanib “is for scleroderma–ILD and not for scleroderma.”

  17. 14-12-2018 | Systemic sclerosis | Case study | Article

    A systemic sclerosis patient who has undergone autologous stem cell transplantation

    American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST) [3] This small trial compared 10 patients who received autologous HSCT with 9 patients given 1.0 g/m 2 intravenous (IV) CYC once per month for 6 months.

  18. 14-12-2018 | Systemic sclerosis | Highlight | Teaser
    Case report

    A systemic sclerosis patient who has undergone autologous stem cell transplantation

    Daniel Furst and Nihal Fathi present a case of a patient with diffuse systemic sclerosis who undergoes autologous hematopoietic stem cell transplantation after failing two other therapies.

  19. 21-03-2019 | Systemic sclerosis | News | Article

    Progressive skin fibrosis should trigger enhanced monitoring in dcSSc

    The study included 1021 patients (mean age 52.0 years) with dcSSc from the EUSTAR (European Scleroderma Trials and Research) database who had a mean disease duration of 7.7 years and baseline modified Rodnan skin score (mRSS) of 7 or more (mean of 16.9).

  20. 21-07-2018 | Systemic sclerosis | Review | Article

    Pain and its management in systemic sclerosis

    Merz EL, Assassi S, Malcarne VL. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0104-4

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.